Advertisement

Ranolazine: Drug overview and possible role in primary microvascular angina management

  • Mattia Cattaneo
    Correspondence
    Corresponding author at: Cardiovascular Medicine Department — Ospedale Regionale di Bellinzona e Valli, San Giovanni (EOC), Via Soleggio, 6500 Bellinzona, Switzerland.
    Affiliations
    Cardiovascular Medicine Department, Ospedale Regionale di Bellinzona e Valli-San Giovanni, Bellinzona, Switzerland
    Search for articles by this author
  • Alessandra Pia Porretta
    Affiliations
    Cardiovascular Medicine Department, Ospedale Regionale di Bellinzona e Valli-San Giovanni, Bellinzona, Switzerland
    Search for articles by this author
  • Augusto Gallino
    Affiliations
    Cardiovascular Medicine Department, Ospedale Regionale di Bellinzona e Valli-San Giovanni, Bellinzona, Switzerland

    University of Zürich, Zürich, Switzerland
    Search for articles by this author
Published:December 22, 2014DOI:https://doi.org/10.1016/j.ijcard.2014.12.055

      Highlights

      • Ranolazine is a novel safe, well-tolerated anti-anginal drug.
      • Ranolazine has been approved as a second-line treatment for stable angina.
      • Primary MVA is characterized by high variability and low response to treatment.
      • Clinical and preclinical evidence suggests ranolazine usefulness in primary MVA.
      • Further trials are needed to investigate the efficacy of ranolazine in primary MVA.

      Abstract

      Ranolazine is a novel well-tolerated anti-ischemic drug, which selectively inhibits late sodium current and exerts metabolic properties without any hemodynamic effect. Ranolazine has been approved as a second-line medical treatment for symptomatic stable coronary artery disease. Primary microvascular angina (MVA) is suspected when angina symptoms occur in patients with demonstrated myocardial ischemia, absence of myocardial disease and normal coronary artery angiography. Recent clinical data suggest that MVA represents a complex entity, which has been increasingly recognized as a significant cause of morbidity. High variability and low response to traditional anti-anginal treatment characterize primary MVA. Despite the fact that clinical and preclinical evidence provides information regarding ranolazine usefulness in primary MVA management, only three recent small randomized trials have investigated this issue. By selecting peer-reviewed literature in Pubmed and Cochrane Library, this review provides an overview on ranolazine pharmacology and efficacy, focusing on recent evidence suggesting its usefulness in management of primary MVA.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to International Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Go A.S.
        • Mozaffarian D.
        • Roger V.L.
        • Benjamin E.J.
        • Berry J.D.
        • Blaha M.J.
        • et al.
        Heart disease and stroke statistics—2014 update: a report from the American Heart Association.
        Circulation. 2014; 129: e28-e292
        • Reis S.E.
        • Holubkov R.
        • Conrad Smith A.J.
        • Kelsey S.F.
        • Sharaf B.L.
        • Reichek N.
        • et al.
        Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: results from the NHLBI WISE study.
        Am. Heart J. 2001; 141: 735-741
        • Arthur H.M.
        • Campbell P.
        • Harvey P.J.
        • McGillion M.
        • Oh P.
        • Woodburn E.
        • et al.
        Women, cardiac syndrome X, and microvascular heart disease.
        Can. J. Cardiol. 2012; 28: S42-S49
        • Lanza G.A.
        • Crea F.
        Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management.
        Circulation. 2010; 121: 2317-2325
        • Lanza G.A.
        • Parrinello R.
        • Figliozzi S.
        Management of microvascular angina pectoris.
        Am. J. Cardiovasc. Drugs. 2014; 14: 31-40
        • European Medicines Agency
        Ranexa (Ranolazine): EU Summary of Product Characteristics.
        (Available at:)
        • Ju Y.K.
        • Saint D.A.
        • Gage P.W.
        Hypoxia increases persistent sodium current in rat ventricular myocytes.
        J. Physiol. 1996; 497: 337-347
        • Meyer M.
        • Keweloh B.
        • Guth K.
        • Holmes J.W.
        • Pieske B.
        • Lehnart S.E.
        • et al.
        Frequency-dependence of myocardial energetics in failing human myocardium as quantified by a new method for the measurement of oxygen consumption in muscle strip preparations.
        J. Mol. Cell. Cardiol. 1998; 30: 1459-1470
        • Antzelevitch C.
        • Belardinelli L.
        • Zygmunt A.C.
        • Burashnikov A.
        • Di Diego J.M.
        • Fish J.M.
        • et al.
        Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties.
        Circulation. 2004; 110: 904-910
        • Fraser H.
        • Belardinelli L.
        • Wang L.
        • Light P.E.
        • McVeigh J.J.
        • Clanachan A.S.
        Ranolazine decreases diastolic calcium accumulation caused by ATX-II or ischemia in rat hearts.
        J. Mol. Cell. Cardiol. 2006; 41: 1031-1038
        • Venkataraman R.
        • Belardinelli L.
        • Blackburn B.
        • Heo J.
        • Iskandrian A.E.
        A study of the effects of ranolazine using automated quantitative analysis of serial myocardial perfusion images.
        JACC Cardiovasc. Imaging. 2009; 2: 1301-1309
        • Hayashida W.
        • van Eyll C.
        • Rousseau M.F.
        • Pouleur H.
        Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease.
        Cardiovasc. Drugs Ther. 1994; 8: 741-747
        • Fu Z.
        • Zhao L.
        • Chai W.
        • Dong Z.
        • Cao W.
        • Liu Z.
        Ranolazine recruits muscle microvasculature and enhances insulin action in rats.
        J. Physiol. 2013; 591: 5235-5249
        • Morrow D.A.
        • Scirica B.M.
        • Chaitman B.R.
        • McGuire D.K.
        • Murphy S.A.
        • Karwatowska-Prokopczuk E.
        • et al.
        Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial.
        Circulation. 2009; 119: 2032-2039
        • Timmis A.D.
        • Chaitman B.R.
        • Crager M.
        Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes.
        Eur. Heart J. 2006; 27: 42-48
        • Aldakkak M.
        • Camara A.K.
        • Heisner J.S.
        • Yang M.
        • Stowe D.F.
        Anolazine reduces Ca2+ overload and oxidative stress and improves mitochondrial integrity to protect against ischemia reperfusion injury in isolated hearts.
        Pharmacol. Res. 2011; 64: 381-392
        • Lamendola P.
        • Nerla R.
        • Pitocco D.
        • Villano A.
        • Scavone G.
        • Stazi A.
        • et al.
        Effect of ranolazine on arterial endothelial function in patients with type 2 diabetes mellitus.
        Atherosclerosis. 2013; 226: 157-160
        • Deshmukh S.H.
        • Patel S.R.
        • Pinassi E.
        • Mindrescu C.
        • Hermance E.V.
        • Infantino M.N.
        • et al.
        Ranolazine improves endothelial function in patients with stable coronary artery disease.
        Coron. Artery Dis. 2009; 20: 343-347
        • Jerling M.
        Clinical pharmacokinetics of ranolazine.
        Clin. Pharmacokinet. 2006; 45: 469-491
        • Chaitman B.R.
        • Pepine C.J.
        • Parker J.O.
        • Skopal J.
        • Chumakova G.
        • Kuch J.
        • et al.
        Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
        JAMA. 2004; 291: 309-316
        • Stone P.H.
        • Gratsiansky N.A.
        • Blokhin A.
        • Huang I.Z.
        • Meng L.
        Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial.
        J. Am. Coll. Cardiol. 2006; 48: 566-575
        • Chaitman B.R.
        • Skettino S.L.
        • Parker J.O.
        • Hanley P.
        • Meluzin J.
        • Kuch J.
        • et al.
        Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina.
        J. Am. Coll. Cardiol. 2004; 43: 1375-1382
        • Koren M.J.
        • Crager M.R.
        • Sweeney M.
        Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE).
        J. Am. Coll. Cardiol. 2007; 9: 1027-1034
        • Morrow D.A.
        • Scirica B.M.
        • Karwatowska-Prokopczuk E.
        • Murphy S.A.
        • Budaj A.
        • Varshavsky S.
        • et al.
        Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
        JAMA. 2007; 297: 1775-1783
        • Montalescot G.
        • Sechtem U.
        • Achenbach S.
        • Andreotti F.
        • Arden C.
        • Budaj A.
        • et al.
        2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology.
        Eur. Heart J. 2013; 34: 2949-3003
        • Scirica B.M.
        • Morrow D.A.
        • Hod H.
        • Murphy S.A.
        • Belardinelli L.
        • Hedgepeth C.M.
        • et al.
        Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial.
        Circulation. 2007; 116: 1647-1652
        • Sossalla S.
        • Maier L.S.
        Role of ranolazine in angina, heart failure, arrhythmias, and diabetes.
        Pharmacol. Ther. 2012; 133: 311-323
        • Jerling M.
        • Huan B.L.
        • Leung K.
        • Chu N.
        • Abdallah H.
        • Hussein Z.
        Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects.
        J. Clin. Pharmacol. 2005; 45: 422-433
        • Food and Drug Administration
        FDA Approved Drug Products: Ranexa (Ranolazine), December 2013.
        (Available at:)
        • Rousseau M.F.
        • Pouleur H.
        • Cocco G.
        • Wolff A.A.
        Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris.
        Am. J. Cardiol. 2005; 95: 311-316
        • Bennett N.M.
        • Arndt T.L.
        • Iyer V.
        • Garberich R.F.
        • Traverse J.H.
        • Johnson Randall K.
        • et al.
        Ranolazine refractory angina registry trial: 1-year results.
        J. Am. Coll. Cardiol. 2011; 57: E1050
        • Camici P.G.
        • Crea F.
        Coronary microvascular dysfunction.
        N. Engl. J. Med. 2007; 356: 830-840
        • Kaski J.C.
        • Rosano G.M.
        • Collins P.
        • Nihoyannopoulos P.
        • Maseri A.
        • Poole-Wilson P.A.
        Cardiac syndrome X: clinical characteristics and left ventricular function. Long-term follow-up study.
        J. Am. Coll. Cardiol. 1995; 25: 807-814
        • Lamendola P.
        • Lanza G.A.
        • Spinelli A.
        • Sgueglia G.A.
        • Di Monaco A.
        • Barone L.
        • et al.
        Long-term prognosis of patients with cardiac syndrome X.
        Int. J. Cardiol. 2010; 140: 197-199
        • Cannon R.O.
        • Camici III, P.G.
        • Epstein S.E.
        Pathophysiological dilemma of syndrome X.
        Circulation. 1992; 85: 883-892
        • Maseri A.
        • Crea F.
        • Kaski J.C.
        • Crake T.
        Mechanisms of angina pectoris in syndrome X.
        J. Am. Coll. Cardiol. 1991; 17: 499-506
        • Botker H.E.
        • Moller N.
        • Ovesen P.
        • Mengel A.
        • Schmitz O.
        • Orskov H.
        • et al.
        Insulin resistance in microvascular angina (syndrome X).
        Lancet. 1993; 342: 136-140
        • Wenger N.K.
        • Chaitman B.
        • Vetrovec G.W.
        Gender comparison of efficacy and safety of ranolazine for chronic angina pectoris in four randomized clinical trials.
        Am. J. Cardiol. 2007; 99: 11-18
        • Mehta P.K.
        • Goykhman P.
        • Thomson L.E.
        • Shufelt C.
        • Wei J.
        • Yang Y.
        • et al.
        Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease.
        JACC Cardiovasc. Imaging. 2011; 4: 514-522
        • Spertus J.A.
        • Winder J.A.
        • Dewhurst T.A.
        • Deyo R.A.
        • Prodzinski J.
        • McDonell M.
        • et al.
        Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease.
        J. Am. Coll. Cardiol. 1995; 25: 333-341
        • Hlatky M.A.
        • Boineau R.E.
        • Higginbotham M.B.
        • Lee K.L.
        • Mark D.B.
        • Califf R.M.
        • et al.
        A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index).
        Am. J. Cardiol. 1989; 64: 651-654
        • Villano A.
        • Di Franco A.
        • Nerla R.
        • Sestito A.
        • Tarzia P.
        • Lamendola P.
        • et al.
        Effects of ivabradine and ranolazine in patients with microvascular angina pectoris.
        Am. J. Cardiol. 2013; 112: 8-13
      1. EuroQol—a new facility for the measurement of health-related quality of life.
        Health Policy. 1990; 16: 199-208
        • Tagliamonte E.
        • Rigo F.
        • Cirillo T.
        • Astarita C.
        • Quaranta G.
        • Marinelli U.
        • et al.
        Effects of ranolazine on noninvasive coronary flow reserve in patients with myocardial ischemia but without obstructive coronary artery disease.
        Echocardiography. 2015; 32: 516-521
      2. ClinicalTrials.gov: Registered Trials.
        (Available at:)